The study showed that Glucagon-like peptide-1 (GLP-1) analogues — drugs developed to treat obesity — likely curb alcohol ...

New research presented at the European Congress on Obesity (ECO 2025) and published in the journal Diabetes, Obesity and ...

Individuals who take liraglutide or semaglutide for weight loss reduce their alcohol consumption by almost two-thirds in four ...

If you're following the GLP-1 (Ozempic and other prescription weight-loss medications) scene, you may have read that the FDA ...

Medicare recipients suffering from obesity must pay out of pocket for weight loss drugs like Wecovy and Zepbound.

Ozempic, Wegovy and Mounjaro can still be expensive, but pharmacy-produced GLP-1 compounds are becoming much more affordable.

Hims & Hers achieved 136% YoY subscriber growth and unveiled ambitious 2030 goals. Discover how precision medicine drives ...

Investors are worried Novo Nordisk's competition with Eli Lilly is heating up and that the first-to-market GLP-1 leader is ...

A man is suing the manufacturers of Ozempic, alleging the diabetes drug caused him to go blind. The medication, containing ...

Wegovy and Ozempic are both semaglutide weight loss medications, but they’re prescribed differently based on who qualifies.

Novo Nordisk A/S' Q1 earnings reveal strong growth in semaglutide-driven sales despite a slight revenue miss. Learn more ...

Novo Nordisk Q1 sales missed estimates despite strong growth in Wegovy and Ozempic, prompting a cut to its 2025 guidance amid ...